Trials / Sponsors / Huiqiang Huang
Huiqiang Huang
Academic / Other · 9 registered clinical trials.
| Status | Trial | Phase | Started |
|---|---|---|---|
| Unknown | Orelabrutinib in Combination With Thiotepa in Refractory and Relapsed Primary CNS Lymphoma Refractory and Relapsed Primary CNS Lymphoma, PCNSL, Non Hodgkin Lymphoma | Phase 1 / Phase 2 | 2021-12-01 |
| Unknown | Tislelizumab in Combination With Lenalidomide in Refractory and Relapsed Elderly Patients With Non-GCB DLBCL Non-GCB/ABC Diffuse Large B-Cell Lymphoma, High-grade B-cell Lymphoma, Follicular Lymphoma Grade IIIb | Phase 1 / Phase 2 | 2021-03-31 |
| Unknown | Ibrutinib With Methotrexate and Temozolomide for Patients With Newly Diagnosed Primary CNS Lymphoma Primary Central Nervous System Lymphoma, PCNSL, Non Hodgkin Lymphoma | Phase 2 | 2020-10-10 |
| Unknown | Camrelizumab in Combination With Apatinib in Refractory and Relapsed DLBCL Diffuse Large B Cell Lymphoma, High-grade B-cell Lymphoma, Follicular Lymphoma Grade IIIb | Phase 1 / Phase 2 | 2020-07-23 |
| Unknown | Toripalimab Plus Rituximab Followed by R-CHOP for Elderly Patients With Untreated Diffused B Cell Lymphoma Diffuse Large B Cell Lymphoma, High-grade B-cell Lymphoma, Follicular Lymphoma Grade IIIb | Phase 1 / Phase 2 | 2020-04-24 |
| Unknown | Rituximab and Pegylated Interferon α-2b in Patients With Indolent B-cell Lymphoma Lymphoma, B-Cell | Phase 2 | 2020-01-15 |
| Completed | Sintilimab in Combination With Chidamide in Refractory and Relapsed ENKTCL Safety and Efficacy | Phase 1 / Phase 2 | 2019-03-29 |
| Unknown | Differences Between Chidamide Taken Daily and Twice a Week in Therapeutic Effect，Pharmacokinetics, Pharmacodyn Lymphoma, Extranodal NK-T-Cell, EBV | Phase 2 | 2016-09-01 |
| Unknown | PEG-ASP+Gemox Regimen and Thalidomide for NK/T Lymphoma Extranodal NK-T-Cell Lymphoma, Nasal and Nasal-Type | Phase 3 | 2013-04-25 |